Is SPRB or GRCE more profitable?

Grace Therapeutics' return on equity of -14.45% beat Spruce Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Spruce Biosciences N/A -155.40% -101.67% Grace Therapeutics N/A -14.45% -13.58%

Is GRCE or NRXP more profitable?

NRx Pharmaceuticals' return on equity of 0.00% beat Grace Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Grace Therapeutics N/A -14.45% -13.58% NRx Pharmaceuticals N/A N/A -202.92%

Does the media prefer GRCE or NRXP?

In the previous week, NRx Pharmaceuticals had 3 more articles in the media than Grace Therapeutics. MarketBeat recorded 5 mentions for NRx Pharmaceuticals and 2 mentions for Grace Therapeutics. Grace Therapeutics' average media sentiment score of 1.00 beat NRx Pharmaceuticals' score of 0.18 indicating that Grace Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Grace Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive NRx Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer GRCE or ADCT?

In the previous week, ADC Therapeutics had 3 more articles in the media than Grace Therapeutics. MarketBeat recorded 5 mentions for ADC Therapeutics and 2 mentions for Grace Therapeutics. Grace Therapeutics' average media sentiment score of 1.00 beat ADC Therapeutics' score of 0.37 indicating that Grace Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Grace Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ADC Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Is VTVT or GRCE more profitable?

vTv Therapeutics' return on equity of 3.96% beat Grace Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets vTv Therapeutics N/A 3.96% 2.86% Grace Therapeutics N/A -14.45% -13.58%

Do analysts recommend GRCE or OGI?

Grace Therapeutics currently has a consensus target price of $6.00, indicating a potential upside of 157.51%. Given Grace Therapeutics' higher probable upside, research analysts plainly believe Grace Therapeutics is more favorable than Organigram Global. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Grace Therapeutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Organigram Global 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33

Grace Therapeutics (GRCE) Competitors

$2.33 -0.06 (-2.51%)

Closing price 04:00 PM Eastern

Extended Trading

$2.33 0.00 (0.00%)

As of 04:10 PM Eastern

Compare

GRCE vs. SPRB, NRXP, ADCT, VTVT, and OGI

Should you buy Grace Therapeutics stock or one of its competitors? MarketBeat compares Grace Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Grace Therapeutics include Spruce Biosciences (SPRB), NRx Pharmaceuticals (NRXP), ADC Therapeutics (ADCT), vTv Therapeutics (VTVT), and Organigram Global (OGI). These companies are all part of the "pharmaceutical products" industry.

How does Grace Therapeutics compare to Spruce Biosciences?

Spruce Biosciences (NASDAQ:SPRB) and Grace Therapeutics (NASDAQ:GRCE) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, valuation, earnings, profitability, risk, analyst recommendations, dividends and media sentiment.

Grace Therapeutics' return on equity of -14.45% beat Spruce Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Spruce Biosciences	N/A	-155.40%	-101.67%
Grace Therapeutics	N/A	-14.45%	-13.58%

Spruce Biosciences presently has a consensus target price of $163.00, indicating a potential upside of 214.25%. Grace Therapeutics has a consensus target price of $6.00, indicating a potential upside of 157.51%. Given Spruce Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe Spruce Biosciences is more favorable than Grace Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Spruce Biosciences	1 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.60
Grace Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Grace Therapeutics has lower revenue, but higher earnings than Spruce Biosciences. Grace Therapeutics is trading at a lower price-to-earnings ratio than Spruce Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Spruce Biosciences	$4.91M	29.05	-$38.97M	-$36.60	N/A
Grace Therapeutics	N/A	N/A	-$7.79M	-$0.48	N/A

In the previous week, Grace Therapeutics had 2 more articles in the media than Spruce Biosciences. MarketBeat recorded 2 mentions for Grace Therapeutics and 0 mentions for Spruce Biosciences. Spruce Biosciences' average media sentiment score of 1.00 equaled Grace Therapeutics'average media sentiment score.

Company	Overall Sentiment
Spruce Biosciences	Positive
Grace Therapeutics	Positive

Spruce Biosciences has a beta of 3.11, suggesting that its share price is 211% more volatile than the broader market. Comparatively, Grace Therapeutics has a beta of 0.37, suggesting that its share price is 63% less volatile than the broader market.

91.7% of Spruce Biosciences shares are held by institutional investors. Comparatively, 6.1% of Grace Therapeutics shares are held by institutional investors. 4.3% of Spruce Biosciences shares are held by company insiders. Comparatively, 11.1% of Grace Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Spruce Biosciences beats Grace Therapeutics on 7 of the 13 factors compared between the two stocks.

How does Grace Therapeutics compare to NRx Pharmaceuticals?

Grace Therapeutics (NASDAQ:GRCE) and NRx Pharmaceuticals (NASDAQ:NRXP) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, earnings, analyst recommendations, valuation, dividends, media sentiment and institutional ownership.

6.1% of Grace Therapeutics shares are held by institutional investors. Comparatively, 4.3% of NRx Pharmaceuticals shares are held by institutional investors. 11.1% of Grace Therapeutics shares are held by company insiders. Comparatively, 6.4% of NRx Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

NRx Pharmaceuticals' return on equity of 0.00% beat Grace Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Grace Therapeutics	N/A	-14.45%	-13.58%
NRx Pharmaceuticals	N/A	N/A	-202.92%

Grace Therapeutics has higher earnings, but lower revenue than NRx Pharmaceuticals. Grace Therapeutics is trading at a lower price-to-earnings ratio than NRx Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Grace Therapeutics	N/A	N/A	-$7.79M	-$0.48	N/A
NRx Pharmaceuticals	$1.23M	104.98	-$28.62M	-$1.09	N/A

In the previous week, NRx Pharmaceuticals had 3 more articles in the media than Grace Therapeutics. MarketBeat recorded 5 mentions for NRx Pharmaceuticals and 2 mentions for Grace Therapeutics. Grace Therapeutics' average media sentiment score of 1.00 beat NRx Pharmaceuticals' score of 0.18 indicating that Grace Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Grace Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
NRx Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Grace Therapeutics presently has a consensus target price of $6.00, indicating a potential upside of 157.51%. NRx Pharmaceuticals has a consensus target price of $38.25, indicating a potential upside of 973.23%. Given NRx Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe NRx Pharmaceuticals is more favorable than Grace Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Grace Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
NRx Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

Grace Therapeutics has a beta of 0.37, meaning that its stock price is 63% less volatile than the broader market. Comparatively, NRx Pharmaceuticals has a beta of 2.14, meaning that its stock price is 114% more volatile than the broader market.

Summary

NRx Pharmaceuticals beats Grace Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Grace Therapeutics compare to ADC Therapeutics?

Grace Therapeutics (NASDAQ:GRCE) and ADC Therapeutics (NYSE:ADCT) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, analyst recommendations, media sentiment, profitability, institutional ownership, risk, dividends and earnings.

In the previous week, ADC Therapeutics had 3 more articles in the media than Grace Therapeutics. MarketBeat recorded 5 mentions for ADC Therapeutics and 2 mentions for Grace Therapeutics. Grace Therapeutics' average media sentiment score of 1.00 beat ADC Therapeutics' score of 0.37 indicating that Grace Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Grace Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ADC Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Grace Therapeutics has higher earnings, but lower revenue than ADC Therapeutics. Grace Therapeutics is trading at a lower price-to-earnings ratio than ADC Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Grace Therapeutics	N/A	N/A	-$7.79M	-$0.48	N/A
ADC Therapeutics	$81.36M	1.68	-$142.62M	-$1.05	N/A

Grace Therapeutics has a beta of 0.37, indicating that its stock price is 63% less volatile than the broader market. Comparatively, ADC Therapeutics has a beta of 1.77, indicating that its stock price is 77% more volatile than the broader market.

Grace Therapeutics has a net margin of 0.00% compared to ADC Therapeutics' net margin of -173.02%. ADC Therapeutics' return on equity of 0.00% beat Grace Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Grace Therapeutics	N/A	-14.45%	-13.58%
ADC Therapeutics	-173.02%	N/A	-44.70%

Grace Therapeutics currently has a consensus target price of $6.00, suggesting a potential upside of 157.51%. ADC Therapeutics has a consensus target price of $6.25, suggesting a potential upside of 481.40%. Given ADC Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe ADC Therapeutics is more favorable than Grace Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Grace Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
ADC Therapeutics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

6.1% of Grace Therapeutics shares are owned by institutional investors. Comparatively, 41.1% of ADC Therapeutics shares are owned by institutional investors. 11.1% of Grace Therapeutics shares are owned by company insiders. Comparatively, 5.4% of ADC Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

ADC Therapeutics beats Grace Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Grace Therapeutics compare to vTv Therapeutics?

vTv Therapeutics (NASDAQ:VTVT) and Grace Therapeutics (NASDAQ:GRCE) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, dividends, media sentiment, analyst recommendations, profitability, institutional ownership and valuation.

17.5% of vTv Therapeutics shares are held by institutional investors. Comparatively, 6.1% of Grace Therapeutics shares are held by institutional investors. 6.0% of vTv Therapeutics shares are held by company insiders. Comparatively, 11.1% of Grace Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Grace Therapeutics has lower revenue, but higher earnings than vTv Therapeutics. vTv Therapeutics is trading at a lower price-to-earnings ratio than Grace Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
vTv Therapeutics	$1.02M	138.17	-$26.97M	-$0.93	N/A
Grace Therapeutics	N/A	N/A	-$7.79M	-$0.48	N/A

vTv Therapeutics presently has a consensus price target of $53.00, indicating a potential upside of 48.17%. Grace Therapeutics has a consensus price target of $6.00, indicating a potential upside of 157.51%. Given Grace Therapeutics' higher possible upside, analysts clearly believe Grace Therapeutics is more favorable than vTv Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
vTv Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Grace Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

vTv Therapeutics' return on equity of 3.96% beat Grace Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
vTv Therapeutics	N/A	3.96%	2.86%
Grace Therapeutics	N/A	-14.45%	-13.58%

vTv Therapeutics has a beta of 0.27, suggesting that its stock price is 73% less volatile than the broader market. Comparatively, Grace Therapeutics has a beta of 0.37, suggesting that its stock price is 63% less volatile than the broader market.

In the previous week, Grace Therapeutics had 2 more articles in the media than vTv Therapeutics. MarketBeat recorded 2 mentions for Grace Therapeutics and 0 mentions for vTv Therapeutics. Grace Therapeutics' average media sentiment score of 1.00 beat vTv Therapeutics' score of 0.00 indicating that Grace Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
vTv Therapeutics	Neutral
Grace Therapeutics	Positive

Summary

Grace Therapeutics beats vTv Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Grace Therapeutics compare to Organigram Global?

Grace Therapeutics (NASDAQ:GRCE) and Organigram Global (NASDAQ:OGI) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, valuation, analyst recommendations, earnings, risk, institutional ownership, profitability and dividends.

Grace Therapeutics has a net margin of 0.00% compared to Organigram Global's net margin of -9.22%. Organigram Global's return on equity of -13.41% beat Grace Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Grace Therapeutics	N/A	-14.45%	-13.58%
Organigram Global	-9.22%	-13.41%	-9.09%

Grace Therapeutics currently has a consensus target price of $6.00, indicating a potential upside of 157.51%. Given Grace Therapeutics' higher probable upside, research analysts plainly believe Grace Therapeutics is more favorable than Organigram Global.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Grace Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Organigram Global	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

6.1% of Grace Therapeutics shares are held by institutional investors. Comparatively, 34.6% of Organigram Global shares are held by institutional investors. 11.1% of Grace Therapeutics shares are held by company insiders. Comparatively, 0.1% of Organigram Global shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Grace Therapeutics has a beta of 0.37, meaning that its share price is 63% less volatile than the broader market. Comparatively, Organigram Global has a beta of 1.43, meaning that its share price is 43% more volatile than the broader market.

Grace Therapeutics has higher earnings, but lower revenue than Organigram Global. Organigram Global is trading at a lower price-to-earnings ratio than Grace Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Grace Therapeutics	N/A	N/A	-$7.79M	-$0.48	N/A
Organigram Global	$185.07M	0.72	-$17.70M	-$0.13	N/A

In the previous week, Grace Therapeutics had 2 more articles in the media than Organigram Global. MarketBeat recorded 2 mentions for Grace Therapeutics and 0 mentions for Organigram Global. Grace Therapeutics' average media sentiment score of 1.00 beat Organigram Global's score of 0.00 indicating that Grace Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Grace Therapeutics	Positive
Organigram Global	Neutral

Summary

Organigram Global beats Grace Therapeutics on 8 of the 15 factors compared between the two stocks.

Get Grace Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GRCE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GRCE vs. The Competition

Export

Metric	Grace Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$38.90M	$3.49B	$6.54B	$12.32B
Dividend Yield	N/A	2.28%	2.68%	5.88%
P/E Ratio	-4.85	11.34	21.43	22.01
Price / Sales	N/A	328.65	530.17	107.90
Price / Cash	N/A	130.96	45.29	53.76
Price / Book	0.48	8.26	10.76	6.41
Net Income	-$7.79M	$23.91M	$3.56B	$337.14M
7 Day Performance	4.95%	3.05%	1.37%	-0.48%
1 Month Performance	5.91%	2.40%	0.81%	0.49%
1 Year Performance	-22.33%	56.35%	30.53%	28.16%

Grace Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GRCE Grace Therapeutics	2.6456 of 5 stars	$2.33 -2.5%	$6.00 +157.5%	-18.4%	$38.90M	N/A	N/A	N/A	Positive News Earnings Report
SPRB Spruce Biosciences	3.1095 of 5 stars	$52.36 flat	$163.00 +211.3%	+893.1%	$144.11M	$4.91M	N/A	20	Positive News High Trading Volume
NRXP NRx Pharmaceuticals	2.4495 of 5 stars	$3.97 flat	$38.25 +863.5%	+21.3%	$143.83M	$1.23M	N/A	2
ADCT ADC Therapeutics	2.4363 of 5 stars	$1.09 -0.5%	$6.25 +476.0%	-57.1%	$138.64M	$81.36M	N/A	310	News Coverage
VTVT vTv Therapeutics	1.9003 of 5 stars	$35.04 flat	$53.00 +51.3%	+126.4%	$138.02M	$1.02M	N/A	9	Negative News Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:GRCE) was last updated on 6/24/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Grace Therapeutics (GRCE) Competitors

GRCE vs. SPRB, NRXP, ADCT, VTVT, and OGI

How does Grace Therapeutics compare to Spruce Biosciences?

Summary

How does Grace Therapeutics compare to NRx Pharmaceuticals?

Summary

How does Grace Therapeutics compare to ADC Therapeutics?

Summary

How does Grace Therapeutics compare to vTv Therapeutics?

Summary

How does Grace Therapeutics compare to Organigram Global?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GRCE vs. The Competition

Grace Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Grace Therapeutics (GRCE) Competitors

GRCE vs. SPRB, NRXP, ADCT, VTVT, and OGI

How does Grace Therapeutics compare to Spruce Biosciences?

Is SPRB or GRCE more profitable?

Do analysts recommend SPRB or GRCE?

Which has stronger earnings and valuation, SPRB or GRCE?

Does the media prefer SPRB or GRCE?

Which has more risk & volatility, SPRB or GRCE?

Do insiders & institutionals hold more shares of SPRB or GRCE?

Summary

How does Grace Therapeutics compare to NRx Pharmaceuticals?

Do institutionals & insiders hold more shares of GRCE or NRXP?

Is GRCE or NRXP more profitable?

Which has higher valuation & earnings, GRCE or NRXP?

Does the media prefer GRCE or NRXP?

Do analysts recommend GRCE or NRXP?

Which has more volatility and risk, GRCE or NRXP?

Summary

How does Grace Therapeutics compare to ADC Therapeutics?

Does the media prefer GRCE or ADCT?

Which has stronger earnings and valuation, GRCE or ADCT?

Which has more risk and volatility, GRCE or ADCT?

Is GRCE or ADCT more profitable?

Do analysts prefer GRCE or ADCT?

Do insiders and institutionals hold more shares of GRCE or ADCT?

Summary

How does Grace Therapeutics compare to vTv Therapeutics?

Do institutionals & insiders have more ownership in VTVT or GRCE?

Which has stronger earnings & valuation, VTVT or GRCE?

Do analysts prefer VTVT or GRCE?

Is VTVT or GRCE more profitable?

Which has more volatility and risk, VTVT or GRCE?

Does the media favor VTVT or GRCE?

Summary

How does Grace Therapeutics compare to Organigram Global?

Is GRCE or OGI more profitable?

Do analysts recommend GRCE or OGI?

Do insiders and institutionals have more ownership in GRCE or OGI?

Which has more volatility and risk, GRCE or OGI?

Which has better earnings & valuation, GRCE or OGI?

Does the media favor GRCE or OGI?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GRCE vs. The Competition

Grace Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools